|
시장보고서
Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
| 리서치사 |
Datamonitor |
| 발행일 |
2009년 05월 |
상품코드 |
90339 |
| 페이지 정보 |
102 pages |
| 가격 |
|
|
Abstract
Introduction
As a result of the increasing switch from live-attenuated and killed
whole-cell vaccines to subunit antigens, there is a need for novel antigen
delivery technologies to improve vaccine efficacy and safety. This report
assesses key strategies, technologies and products for vaccine antigen
delivery. It provides an overview of opportunities and challenges for the
sector and a future outlook.
Scope of this research
In-depth analysis of key vaccine antigen delivery technologies Thorough
assessment of the potential for selected vaccine antigen delivery technologies
Review of industry and academic stakeholder opinions involved in the vaccine
antigen delivery sector In-depth discussion of key opportunities and risks for
novel vaccine antigen delivery technologies
Research and analysis highlights
There is a significant need for novel vaccine antigen delivery technologies
following the increasing switch from live-attenuated and killed whole-cell
vaccines to subunit antigens. Key drivers for the sector are the need for
increased immunogenicity and safety as well as for vaccine formulations
combining delivery systems and adjuvant.
Virus-like particles and virosomes, both benefiting from the successful track
record of already marketed vaccines, have the best potential in the short- to
mid term. ISCOM-based technologies could be valuable for therapeutic vaccines,
while liposomes and micro-/nanoparticles will not play a major role for
vaccine delivery in the foreseeable future.
Antigen stability, safety and immunogenicity are the key hurdles for novel
antigen delivery technologies. In times of restricted healthcare budgets,
pricing and manufacturing costs need to be kept to a minimum. The limited
understanding of the detailed molecular mechanisms for many technologies poses
a further challenge.
Key reasons to purchase this research
- Review profiles of key vaccine antigen delivery technologies both marketed
and in clinical development and assess their future potential
- Gain insight into the current state of vaccine antigen delivery
technologies and their future opportunities and challenges
- Benefit from opinions of key industry and academic stakeholders in the
vaccine antigen delivery field
Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the vaccine delivery technologies market
- Related reports
- Upcoming related reports
ANTIGEN TYPES FOR HUMAN VACCINES
- Historic overview of antigen development for vaccines
- Live-attenuated pathogens
- Inactivated/killed pathogens
- Protein-based subunit or toxoid vaccines
- Polysaccharide subunit vaccines
- DNA/RNA vaccines
RATIONALE FOR THE DEVELOPMENT OF NOVEL ANTIGEN DELIVERY SYSTEMS
- Novel delivery vehicles could improve the efficacy of subunit vaccines
- Improved antigen stability is a key need, particularly for mucosal
administration routes
- Delivery vehicles with additional adjuvant qualities could enable the
development of vaccines against challenging indications
CHALLENGES FOR THE DEVELOPMENT OF NOVEL ANTIGEN DELIVERY VEHICLES
- Cost containment could become a key hurdle for novel vaccine delivery
vehicles
- More research is needed to understand the molecular mechanisms of antigen
delivery
- The conservative attitude of regulators towards novel adjuvants and
delivery vehicles is a key challenge
- Various new technologies are in development as antigen delivery vehicles
BACTERIAL/VIRAL VECTORS
- Summary
- General considerations
- Bacterial/viral vector vaccines in development
- Acambis/Sanofi Pasteur - ChimeriVax technology
- Crucell - Advax technology
- Bavarian Nordic - MVA-BN
- Datamonitor assessment
LIPOSOMES
- Summary
- General considerations
- Liposomal vaccines in development
- Merck Serono - Stimuvax/L-BLP25
- NasVax - VaxiSome technology
- Datamonitor assessment
VIROSOMES
- Summary
- General considerations
- Marketed and pipeline virosomal vaccines
- Crucell - Immunopotentiating reconstituted influenza virosome (IRIV)
technology
- Pevion Biotech - PeviPro and PeviTer virosome technologies
- Datamonitor assessment
VIRUS-LIKE PARTICLES
- Summary
- General considerations
- Marketed and pipeline VLP vaccines
- Cytos Biotechnology - Immunodrug platform
- Novavax - baculovirus-based VLPs
- Others
- Datamonitor assessment
ISCOM/ISCOMATRIX
- Summary
- General considerations
- ISCOM/ISCOMATRIX-based vaccines in development
- CSL and licensees - ISCOMATRIX
- Datamonitor assessment
MICROPARTICLES/NANOPARTICLES
- Summary
- General considerations
- Micro-/nanoparticle technologies in development for vaccines
- PLGA - poly(-lactide co-glycolide)
- Chitosan
- Datamonitor assessment
BIBLIOGRAPHY
APPENDIX
- Contributing experts
- Academic key opinion leaders
- Industry key opinion leaders
- Conferences
- Report methodology
TABLES
- Table: Key marketed live-attenuated vaccines, 7MM, May 2009
- Table: Summary of key antigen delivery technologies in development
- Table: Viral and bacterial vector-based vaccines for prophylactic vaccine
applications, May 2009
- Table: Viral and bacterial vector-based vaccines for therapeutic vaccine
applications, May 2009
- Table: SWOT analysis: bacterial/viral vector based vaccine delivery
- Table: Key pipeline liposomal vaccines
- Table: SWOT analysis - liposome-based vaccine delivery
- Table: Key marketed and pipeline virosomal vaccines
- Table: SWOT analysis - virosome-based vaccine delivery
- Table: Key marketed and pipeline virus-like particle (VLP)-based vaccines
- Table: SWOT analysis - virus-like particle (VLP)-based vaccine delivery
- Table: Key pipeline vaccines based on ISCOMATRIX
- Table: SWOT analysis - ISCOM/ISCOMATRIX-based vaccine delivery
- Table: Key micro- and nanoparticle technologies in development
- Table: SWOT analysis - microparticle-/nanoparticle-based vaccine delivery
FIGURES
- Figure: History of vaccine antigen design and delivery
- Figure: Unmet needs in antigen delivery
- Figure: Drivers and resistors for the development of antigen delivery
vehicles
- Figure: Public sector immunization cost per child in the US ($), 1975 -
2008
- Figure: Vector vaccines
- Figure: Liposomal vaccine delivery
- Figure: Virosome structure
- Figure: Production of virus-like particles (VLPs)
|
